Companies: 10,795·Total market cap: $144.5T
Cytek Biosciences, Inc.

Cytek Biosciences, Inc.

CTKBNASDAQHealthcare● Active
$4.02
$-0.07(-1.60%)
Market Cap$519721427
P/E Ratio—
52W High$6.18
52W Low$2.9
Free Cash FlowFinancialsRevenue

Cytek Biosciences, Inc. (CTKB) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

CTKB · free cash flow · updated Jun 8, 2026

Core FCF metrics

Free cash flow was −$8.8M for FY2025 (fiscal year ending 2025-12-31), down 140.1% year-over-year The FCF margin was -4.3%.

FY2025 Free Cash Flow−$8.8M▼ -140.1% YoY
Trailing 12M (TTM)−$12.7Mtrailing 4 quarters sum
FCF Margin-4.3%−$8.8M ÷ revenue
3-Year CAGRN/AN/A — contains negative FCF
5-Year CAGRN/AN/A — contains negative FCF
FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0
Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

Positive FCFNegative FCF
Free Cash Flow
YoY Growth %
ctkb free cash flow history · ctkb free cash flow chart · ctkb free cash flow growth rate · ctkb free cash flow last 10 years

Annual free cash flow data

Fiscal YearFree Cash FlowYoY ChangeFCF Margin
FY2025Latest−$8.8M▼ 140.1%-4.3%
FY2024$21.9M▲ +4713.7%10.9%
FY2023$454,000▲ +102.1%0.2%
FY2022−$22.1M▼ 8407.9%-13.5%
FY2021$266,000▼ 98.0%0.2%
FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP
ctkb free cash flow 2025 · ctkb free cash flow 2024 · ctkb free cash flow 2023 · ctkb operating cash flow

FCF valuation metrics

Cytek Biosciences, Inc. (CTKB) reported negative free cash flow of −$0.01B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)
N/A
Free Cash Flow ÷ Market Cap
per FMP freeCashFlowYieldTTM definition
FCF per Share (TTM)
N/A
TTM FCF ÷ Shares Outstanding
Price / FCF
N/A
Share Price ÷ FCF per Share
EV / FCF (TTM)
N/A
Enterprise Value basis
!

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31
ctkb price to free cash flow · ctkb free cash flow yield · ctkb free cash flow per share · ctkb price to cash flow ratio

Cash flow statement summary

For FY2025, Cytek Biosciences, Inc. generated −$4.7M in operating cash flow and spent 4M in capital expenditures, yielding −$8.8M in free cash flow.

Operating Activities
−$4.7M
Cash from core business operations
2025-12-31
Investing Activities
+$10.1M
CapEx, acquisitions & investments
2025-12-31
Financing Activities
−$13.4M
Buybacks, dividends & debt
2025-12-31
FCF FormulaOperating CF (−$4.7M) − |CapEx| (4M) = FCF (−$8.8M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →
ctkb cash flow statement · ctkb cash flow statement 2025 · ctkb operating cash flow · ctkb cash flow from operations

Free cash flow vs peers (Healthcare)

#CompanyFree Cash FlowYoY
#1
Cytek Biosciences, Inc.
Cytek Biosciences, Inc.YOU
CTKB
−$8.8M-140.1%
#2
Johnson & Johnson
Johnson & Johnson
JNJ
$19.70B-0.7%#3
AbbVie Inc.
AbbVie Inc.
ABBV
$17.82B-0.1%#4
UnitedHealth Group Incorporated
UnitedHealth Group Incorporated
UNH
$16.07B-22.4%#5
Eli Lilly and Company
Eli Lilly and Company
LLY
$8.97B+2065.6%
Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Cytek Biosciences, Inc. (CTKB) reported free cash flow of −$8.8M for FY2025 (fiscal year ending 2025-12-31), down 140.1% year-over-year. The FCF margin was -4.3%.

Based on available data, Cytek Biosciences, Inc. has maintained positive free cash flow for at least 4 fiscal year(s). FCF peaked at $21.9M in FY2024.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.
RevenueFinancial statementsNet incomeEarningsForecastPrice historyMarket capCash on handP/E ratio

Frequently asked questions

CTKB free cash flow · 8 questions

Cytek Biosciences, Inc. free cash flow was −$8.8M for FY2025, down 140.1% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$12.7M.

CTKB free cash flowCTKB FCFCTKB FCF 2025CTKB free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Cytek Biosciences, Inc. · Cytek Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026